Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

Source: 
Xconomy
snippet: 

The genetic mutations that cause epilepsy don’t stop there. Praxis Precision Medicines CEO Marcio Souza says research also links these genes to other neurological conditions. The biotech startup is turning that research into new neuro drugs and it’s coming out of stealth to share details about its science and its pipeline, which already has two programs in mid-stage testing.